Navigation Links
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Date:6/4/2011

CHICAGO, June 4, 2011 /PRNewswire/ -- Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials.  This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival.  Biomarkers are of scientific interest as, if validated, they could be used as a surrogate for a clinical endpoint and may help accelerate the clinical trial process.  

Results of the study titled, "Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC)" indicated that pre-treatment, CTCs and lactate dehydrogenase (LDH), both alone and in combination, were prognostic biomarkers, while baseline prostate-specific antigen (PSA) was not.  Following the start of treatment, CTC counts were measured at four, eight and 12 weeks.  The data suggest that changes in CTC counts can predict overall survival during treatment.  Data also indicated LDH was strongly associated with survival.  

"Establishing CTCs as a biomarker or part of a biomarker panel that is a surrogate-endpoint for survival would be an important step toward our goal of enabling shorter trials and more rapid drug approvals in prostate cancer," said Howard Scher, M.D., the lead author of the study and chief of the genitourinary oncology service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering Cancer Center. 

"As the only device with regulatory clearance to capture and count CTCs, we are excited that the data substantiates the prognostic value of CELLSEARCH®," said Robert McCormack, Ph.D. and Head of Technology Innovation at Veridex, LLC.  "We look forward to further investigating the potential predictive benefit of CTCs in metastatic prostate cancer clinical trials as there are limited ways of assessing therapeutic benefit in this disease, especially when it has metastasized to the bone."

Additional studies are underway to further validate CTCs as a surrogate endpoint in metastatic prostate cancer studies.

Study Design

The CTC analysis was conducted to determine if CTCs could be used as a surrogate for overall survival.  It was performed in 900 of the 1195 enrolled study patients with metastatic castration-resistant prostate cancer post-docetaxel being treated with either abiraterone acetate plus prednisone or placebo plus prednisone.  CTCs were counted (cells/7.5 mL) along with other biomarkers including PSA, LDH, hemoglobin, alkaline phosphatase at screening and baseline and post-baseline at four, eight and 12 weeks. Analyses were conducted for these biomarkers individually and collectively.

Veridex provided product support for the study. 

Dr. Howard Scher has provided consulting services to the company. 

Additional Data Presented at ASCO Substantiates In Vitro Diagnostic Use of CELLSEARCH® CTC Test

An independent study investigating the in vitro diagnostic use of CTC testing found that the number of CTCs in the blood may help physicians more reliably assess treatment benefit for patients with metastatic breast cancer.  The study, a large-scale retrospective analysis using blinded data to create a pooled dataset of 841 patients from cancer centers around the world, found that CTC count at or above the threshold of five was reliably associated with disease progression.  Further, the predictive value of CTCs was not affected by treatment type (chemotherapy, endocrine therapy, biologic therapy), tumor type (hormone receptor positive/negative, HER2 positive/negative), or sites of disease involvement.  The study was lead by Minetta Liu, M.D., Georgetown Lombardi Comprehensive Cancer Center and will be presented during a poster session on Monday, June 6th, 2011.

Dr. Minetta Liu has provided consulting services to the company. 

About Circulating Tumor Cells

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream.  The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

About CELLSEARCH® CTC Test

CELLSEARCH® is the first and only regulatory-cleared in vitro diagnostic test to capture and count CTCs to determine the prognosis of patients with metastatic breast, colorectal or prostate cancer.  The test can be administered at any time during the course of therapy as a routine blood test.  It is used in combination with other tests and a clinician's assessment, to provide a more complete picture of a patient's prognosis.

About Veridex, LLC

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value diagnostic oncology products.  Veridex's IVD products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care.  Veridex's Clinical Research Solutions provide tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies.  For more information, visit www.veridex.com

About Abiraterone

In the U.S., abiraterone acetate is marketed as ZYTIGA™ by Centocor Ortho Biotech, Inc. an affiliate of Veridex.  It was developed by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc. and was approved by the U.S. Food & Drug Administration on April 28, 2011.  Marketing authorization applications for ZYTIGA have been filed with other regulatory authorities around the world.  For more information about ZYTIGA, visit www.ZYTIGA.com.


'/>"/>
SOURCE Veridex, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
2. American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA
3. American Stroke Association Late-Breaking Science Report: Antiplatelet Drug May Be Better Than Aspirin in Preventing Recurrent Strokes
4. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients
5. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
6. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
7. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
8. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
11. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
Breaking Medicine News(10 mins):